Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems.
This milestone marks the first clinical use of Remplir within the DoD / VA network and represents an important step in Orthocell’s U.S. commercialisation strategy, demonstrating the Company’s ability to rapidly translate regulatory and procurement approvals into real‑world surgical adoption. The surgery was conducted at a military base hospital in Ohio.
As announced on 15 April 2026, Orthocell secured approval for Remplir to be supplied across the U.S. Department of Defense and Veterans Affairs hospital networks, providing access to approximately 51 DoD military hospitals and 170 VA medical centres nationwide.
The rapid completion of a first surgical case highlights early engagement from surgeons within these systems and reinforces the strength of Orthocell’s existing U.S. distributor footprint, which spans 17 states and supports efficient onboarding and in‑theatre case support. These distributors will now support further uptake of Remplir across the DoD and VA systems as part of Orthocell’s broader US commercialisation strategy.
Orthocell Managing Director Paul Anderson said: “We are extremely pleased to see Remplir translated into its first surgical case within the U.S. DoD and VA hospital network so quickly after receiving approval. It’s a strong validation of our commercial strategy and surgeon engagement efforts while demonstrating the value of our distribution network. This milestone underscores both the clinical relevance of Remplir for complex nerve injuries and our team’s ability to execute rapidly once access is secured. Military and veteran healthcare systems manage some of the most challenging trauma cases, and early surgical uptake is an encouraging signal as we continue to expand activity across these hospitals.”
The initial use of Remplir within the DoD / VA hospital network builds on Orthocell’s broader rollout of Remplir across the U.S. hospital system and the strong commercialisation progress being achieved to date. With expanding hospital access, growing surgeon engagement and increasing case activity, the Company continues to make excellent progress with its Remplir rollout across the U.S.
Orthocell will continue to work closely with its U.S. distribution partners and surgeon network to support further uptake of Remplir™ across the DoD and VA systems as part of its broader U.S. commercialisation strategy.